Serum Level of MiR-609 and Its Clinical Prognostic Value in Patients with Thalassemia.
10.7534/j.issn.1009-2137.2019.06.036
- Author:
Ming-Quan WANG
1
;
Ling-Li CHENG
2
;
Jing-Jing GAO
2
;
Ren-Wei XIE
2
;
Li-Ping LIN
2
;
Jian-Zhong YANG
3
;
Rong-Yu XU
4
Author Information
1. Department of Blood Transfusion, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou 362000, Fujian Province, China,E-mail: jjgg12@163.com.
2. Department of Blood Transfusion, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou 362000, Fujian Province, China.
3. Department of Hematology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou 362000, Fujian Province, China.
4. Department of Oncology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou 362000, Fujian Province, China,E-mail: 922021wmq@sohu.com.
- Publication Type:Journal Article
- MeSH:
Biomarkers, Tumor;
Humans;
MicroRNAs;
Prognosis;
ROC Curve;
Thalassemia;
genetics
- From:
Journal of Experimental Hematology
2019;27(6):1933-1937
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the level of serum microRNA-609 and its clinical prognostic value in patients with thalassemia.
METHODS:One hundred and twenty-seven patients with thalassemia treated in our hospital from April 2017 to April 2018 were selected, 100 healthy persons were selected as control group. The changes of miR-609 were analyzed by RT-PCR, the relationship between miR-609 and clinical indicators of thalassemia was analyzed, and the prognostic risk factors of thalassemia were evaluated by multivariate logistic regression analysis.
RESULTS:The relative expression level of miR-609 in thalassemia patients was 3.17±0.24, which was significantly higher than that in control group (P<0.05). The levels of ALT, Plt and MCH in patients with high expression of miR-609 were significantly higher than those in patients with low expression of miR-609 (P<0.05). The levels of Hb and sICAM-1 in patients with high expression of miR-609 were significantly lower than those in patients with low expression of miR-609 (P<0.05). There was no correlation between the level of miR-609 and the patient's sex, age and AST (P>0.05). The incidence rate of mild anemia in high expression group was significantly lower than that in low expression group (P<0.05). There was no correlation between the level of miR-609 and the incidence rate of moderate anemia (P>0.05). The number of patients with severe anemia in the miR-609 high expression group was higher than that in miR-609 low expression group (P<0.05). The incidence rate of dizziness, fatigue and fever in patients with miR-609 high expression group was significantly higher than those in patients with miR-609 low expression (P<0.05). There was no correlation between the level of miR-609 and the incidence rate of nausea in patients with thalassemia. ROC curve showed that the AUC value of microRNA-609 was 0.862, the sensitivity was 83.6%, and the specificity was 84.1%, which suggested that miR-609 had a high diagnostic value for thalassemia. Multivariate logistic regression analysis showed that MCH and mir-609 were risk factors for poor prognosis of thalassemia patients.
CONCLUSION:The increased level of serum miR-609 in patients with thalassemia is a risk factor for poor prognosis and can be used as a reference index for evaluating the efficacy for patients.
